Navigation Links
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
Date:9/28/2007

e on what we believe is most critical to our future success -- building and advancing our pipeline."

Idenix currently has a non-nucleoside reverse transcriptase inhibitor (NNRTI), IDX899, for the treatment of HIV-1 that is being evaluated in phase I/II clinical testing. The company also has a comprehensive HCV discovery effort, comprised of a next-generation nucleoside polymerase inhibitor program, including IDX102 and IDX184, which are currently being evaluated in advanced preclinical testing, and HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor programs.

As a result of this restructuring, Idenix will incur between $5 million and $10 million in charges, primarily associated with one-time employee severance benefits and the write-off of certain assets. The company continues to expect to end 2007 with between $100 million and $110 million of cash, cash equivalents and marketable securities. Idenix estimates that this restructuring will result in savings of $40 million to $45 million on an annual basis.

"We have taken the steps necessary to streamline our organization and significantly reduce our expenses, while continuing to maintain the strength of our balance sheet," said Ronald Renaud, Jr., chief financial officer of Idenix. "We believe that we are now well-positioned to fund the advancement of our HIV and HCV discovery and development programs through 2009."

About Idenix/Novartis Collaboration

Idenix and Novartis Pharma AG established a collaboration in May 2003, at which point Novartis became a majority shareholder in Idenix. Currently, Novartis owns 56% of Idenix and has first right of refusal to Idenix's pipeline.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caus
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Front-face detection for high-concentrate, opaque or solid sample
4. Concentrated solar energy project wins Innovation Days prizes
5. Wisconsin stands at the center of scientific efforts to avert flu epidemics
6. Thompsons HHS legacy will include efforts to combat disease in Africa
7. Efforts to avoid friendly fire spawned ancestor of todays RFID
8. Manufacturing group says efforts led to big improvements
9. Madison grid computing efforts attack big research questions
10. Californian stem-cell efforts get new rules, attract lawsuits
11. Tech Council passes E-Learning efforts for Northern Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines ... forecast of revenue. The Automatic patient billing market in ... by 2018, at a developing CAGR of 7.2% from ... the Asian Automatic patient billing market, to get an ... a glimpse of the segmentation of this market in ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report defines ... forecast of revenue. The Orthopedic braces and support systems market ... by 2018, at a developing CAGR of 4.4% from 2013 ... Orthopedic braces and support systems market, to get an idea ... of the segmentation of orthopedic braces and support systems market ...
Breaking Biology Technology:NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... Calif., Oct. 19, 2011 Process automation specialist Endress+Hauser ... company that develops, produces and distributes sensors, hardware and ... to strengthen its position in the area of biotechnology ... important role in the future, not only in the ...
... Applications International Corporation (SAIC) (NYSE: SAI ) ... National Institute of Allergy and Infectious Diseases (NIAID), part ... preclinical services for the development of biopharmaceutical products for ... the end of fiscal year 2011.  The total funding ...
... NEW YORK, Oct. 19, 2011 ... research report is available in its ... Erythematosus Therapeutics (SLE) - Pipeline Assessment ... http://www.reportlinker.com/p0656881/Systemic-Lupus-Erythematosus-Therapeutics-SLE---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
Cached Biology Technology:Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 2Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company 3SAIC Awarded Contract by National Institute of Allergy and Infectious Diseases 2Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 2Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 3Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 4Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 5Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 6Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 7Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 8Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 9Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018 10
(Date:10/16/2014)... have a new synthesis of recent research findings to ... in the two states. , The Ecology and ... Washington: A Synthesis of the Relevant Biophysical Science and ... published by the U.S. Forest Service,s Pacific Northwest Research ... managers for a synthesis of the large body of ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... Virus (HCV) infects up to 500,000 people in the ... is the single biggest cause of people requiring a ... with groups across Europe and the USA, scientists from ... may be a significant step towards a vaccine. ...
... The Simons Foundation, through its Autism Research Initiative, has ... University Cell and DNA Repository (RUCDR) to establish a ... will be collected from 2,000 families that have a ... this project is known, will constitute the core resource ...
... may be to blame for the gradual extinction of ... according to Ulrich Kutschera and colleagues from the University ... in Austria. Their findings show that human-induced temperature ... of Austria may have led to the near extinction ...
Cached Biology News:Possible hepatitis C vaccine 2Rutgers Genetics receives $7.8 million for autism research 2Rutgers Genetics receives $7.8 million for autism research 3Role reversal as humans suck life out of leeches 2
1M stock solution (238mg/ml)...
...
Request Info...
... peptide derived from the C-terminal region catalytic ... C zeta isoform (PKCzeta). Specificity: Reacts ... Recognizes PKCzeta and PKMzeta (PKCzeta II) ... Reactivity: Mouse Rat (positive controls: mouse and ...
Biology Products: